Pular para o conteúdo
Síndrome Kallmann
ORPHA:478CID-10 · E23.0CID-11 · 5A61.2DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Face / craniofacialInício infantilHerança AD/AR/Complex/XL
Também conhecida comoSíndrome de KalmanSíndrome de hipogonadismo hipogonadotrópico congénito com anosmiaSKHHC
Sinônimos clínicos: Síndrome de hipogonadismo hipogonadotrópico congénito com anosmia · Sequência patológica olfato-genital

A Síndrome de Kallmann (SK) é uma condição genética que afeta o desenvolvimento, caracterizada por dois problemas principais: o hipogonadismo hipogonadotrófico congênito (HHC), que é um problema hormonal presente desde o nascimento onde o corpo não produz hormônios sexuais em quantidade suficiente (isso acontece pela falta de um hormônio importante chamado GnRH); e a anosmia (perda total do olfato) ou hiposmia (olfato reduzido), que estão ligadas ao desenvolvimento incompleto ou à ausência dos bulbos olfatórios (as partes do cérebro responsáveis pelo olfato).

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

Síndrome de Kallmann é uma condição caracterizada por puberdade atrasada ou ausente e por um sentido de olfato prejudicado.

Esse distúrbio é uma forma de hipogonadismo hipogonadotrópico, que é uma condição resultante da falta de produção de certos hormônios que dirigem o desenvolvimento sexual. Esses hormônios são normalmente produzidos em uma parte do cérebro chamada hipotálamo. Homens nascidos com hipogonadismo hipogonadotrópico frequentemente apresentam um pênis incomumente pequeno (micropênis) e testículos não descidos (criptorquidia). Na puberdade, a maioria das pessoas afetadas não desenvolve características sexuais secundárias, como o crescimento de pelos faciais e o aprofundamento da voz nos homens, o início da menstruação e o desenvolvimento das mamas nas mulheres, e um surto de crescimento em ambos os sexos. Sem tratamento, a maioria dos homens e mulheres afetados não consegue ter filhos biológicos (inférteis).

Na síndrome de Kallmann, o sentido de olfato está diminuído (hiposmia) ou completamente ausente (anosmia). Essa característica distingue a síndrome de Kallmann da maioria das outras formas de hipogonadismo hipogonadotrópico, que não afetam o sentido de olfato. Muitas pessoas com síndrome de Kallmann não percebem que são incapazes de detectar odores até que a deficiência seja descoberta por meio de testes.

A síndrome de Kallmann pode apresentar uma grande variedade de sinais e sintomas adicionais. Estes incluem a falha no desenvolvimento de um rim (agenesia renal unilateral), anomalias nos ossos dos dedos das mãos ou dos pés, fissura labial com ou sem abertura no palato (fissura palatina), movimentos oculares anormais, perda auditiva e anomalias no desenvolvimento dos dentes. Alguns indivíduos afetados apresentam uma característica chamada sinquinesia bimanual, na qual os movimentos de uma mão são espelhados pela outra mão. A sinquinesia bimanual pode dificultar a realização de tarefas que exigem que as mãos se movam separadamente, como tocar um instrumento musical.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

A Síndrome de Kallmann (SK) é uma condição genética que afeta o desenvolvimento, caracterizada por dois problemas principais: o hipogonadismo hipogonadotrófico congênito (HHC), que é um problema hormonal presente desde o nascimento onde o corpo não produz hormônios sexuais em quantidade suficiente (isso acontece pela falta de um hormônio importante chamado GnRH); e a anosmia (perda total do olfato) ou hiposmia (olfato reduzido), que estão ligadas ao desenvolvimento incompleto ou à ausência dos bulbos olfatórios (as partes do cérebro responsáveis pelo olfato).

Pesquisas ativas
3 ensaios
22 total registrados no ClinicalTrials.gov
Publicações científicas
918 artigos
Último publicado: 2026 Apr 15

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
3.75
Europe
Início
Adolescent
+ childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: E23.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
13 sintomas
🦴
Ossos e articulações
10 sintomas
😀
Face
6 sintomas
🧠
Neurológico
6 sintomas
👁️
Olhos
4 sintomas
🫃
Digestivo
3 sintomas

+ 35 sintomas em outras categorias

Características mais comuns

90%prev.
Hiposmia
Muito frequente (99-80%)
90%prev.
Micropênis
Muito frequente (99-80%)
90%prev.
Anosmia
Muito frequente (99-80%)
90%prev.
Disfunção erétil
Muito frequente (99-80%)
90%prev.
Fertilidade diminuída
Muito frequente (99-80%)
90%prev.
Puberdade atrasada
Muito frequente (99-80%)
87sintomas
Muito frequente (11)
Frequente (4)
Ocasional (29)
Sem dados (43)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 87 características clínicas mais associadas, ordenadas por frequência.

HiposmiaHyposmia
Muito frequente (99-80%)90%
MicropênisMicropenis
Muito frequente (99-80%)90%
Muito frequente (99-80%)90%
Disfunção erétilErectile dysfunction
Muito frequente (99-80%)90%
Fertilidade diminuídaDecreased fertility
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico918PubMed
Últimos 10 anos200publicações
Pico202248 papers
Linha do tempo
2026Hoje · 2026🧪 1989Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

23 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, Multigenic/multifactorial, X-linked recessive.

Curadoria gene-doença

fontes oficiais
TCF12
CHD7ATP-dependent chromatin remodeler CHD7Disease-causing germline mutation(s) inAltamente restrito
MECANISMO DE DOENÇA

CHARGE syndrome

Common cause of congenital anomalies. Is characterized by a non-random pattern of congenital anomalies including choanal atresia and malformations of the heart, inner ear, and retina.

OUTRAS DOENÇAS (6)
hypogonadotropic hypogonadism 5 with or without anosmiaCHD7-related CHARGE syndromeKallmann syndromehypogonadotropic hypogonadism
HGNC:20626UniProt:Q9P2D1
NSMFNMDA receptor synaptonuclear signaling and neuronal migration factorDisease-causing germline mutation(s) inRestrito
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 9 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Hipocampo
462.4 TPM
Brain Anterior cingulate cortex BA24
404.5 TPM
Córtex cerebral
370.5 TPM
Brain Frontal Cortex BA9
339.6 TPM
Cérebro - Amígdala
313.9 TPM
OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 9 with or without anosmiahypogonadotropic hypogonadism
HGNC:29843UniProt:Q6X4W1
KISS1RKiSS-1 receptorDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 8 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). HH8 inheritance pattern is autosomal recessive.

EXPRESSÃO TECIDUAL(Baixa expressão)
Hipotálamo
3.2 TPM
Linfócitos
2.5 TPM
Brain Nucleus accumbens basal ganglia
2.0 TPM
Pituitária
1.8 TPM
Brain Anterior cingulate cortex BA24
1.0 TPM
OUTRAS DOENÇAS (5)
hypogonadotropic hypogonadism 8 with or without anosmiacentral precocious puberty 1genetic central precocious puberty in malehypogonadotropic hypogonadism
HGNC:4510UniProt:Q969F8
HS6ST1Heparan-sulfate 6-O-sulfotransferase 1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (1)
HS-GAG biosynthesis
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 15 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
60.9 TPM
Córtex cerebral
57.3 TPM
Glândula adrenal
52.5 TPM
Brain Frontal Cortex BA9
51.2 TPM
Rim - Medula
47.5 TPM
OUTRAS DOENÇAS (3)
hypogonadotropic hypogonadismKallmann syndromehypogonadotropic hypogonadism 15 with or without anosmia
HGNC:5201UniProt:O60243
NDNFProtein NDNFDisease-causing germline mutation(s) inRestrito
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 25 with anosmia

A form of hypogonadotropic hypogonadism, a group of disorders characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone, and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). HH25 is an autosomal dominant form with anosmia, characterized by intrafamilial variable expressivity and incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
44.6 TPM
Ovário
32.4 TPM
Testículo
18.9 TPM
Próstata
8.4 TPM
Cervix Endocervix
8.1 TPM
OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 25 with anosmiaKallmann syndrome
HGNC:26256UniProt:Q8TB73
FGF17Fibroblast growth factor 17Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerPI-3K cascade:FGFR3Negative regulation of FGFR3 signaling
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 20 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
128.3 TPM
Cérebro - Hemisfério cerebelar
108.3 TPM
Córtex cerebral
23.4 TPM
Brain Frontal Cortex BA9
16.9 TPM
Tireoide
13.1 TPM
OUTRAS DOENÇAS (3)
hypogonadotropic hypogonadism 20 with or without anosmiaKallmann syndromehypogonadotropic hypogonadism
HGNC:3673UniProt:O60258
FGF8Fibroblast growth factor 8Disease-causing germline mutation(s) (loss of function) inModerado
VIAS BIOLÓGICAS (1)
Formation of the posterior neural plate
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 6 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.2 TPM
Córtex cerebral
0.6 TPM
Linfócitos
0.6 TPM
Brain Frontal Cortex BA9
0.6 TPM
Brain Anterior cingulate cortex BA24
0.5 TPM
OUTRAS DOENÇAS (8)
hypogonadotropic hypogonadism 6 with or without anosmiamicroform holoprosencephalyKallmann syndromehypogonadotropic hypogonadism
HGNC:3686UniProt:P55075
DUSP6Dual specificity protein phosphatase 6Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
ERKs are inactivated
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 19 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Adipose Visceral Omentum
91.5 TPM
Baço
81.5 TPM
Pulmão
74.6 TPM
Mama
61.7 TPM
Tecido adiposo
56.6 TPM
OUTRAS DOENÇAS (3)
hypogonadotropic hypogonadism 19 with or without anosmiaKallmann syndromehypogonadotropic hypogonadism
HGNC:3072UniProt:Q16828
DCCNetrin receptor DCCDisease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (7)
Caspase activation via Dependence Receptors in the absence of ligandDCC mediated attractive signalingRole of second messengers in netrin-1 signalingRegulation of commissural axon pathfinding by SLIT and ROBONetrin-1 signaling
MECANISMO DE DOENÇA

Mirror movements 1

A disorder characterized by contralateral involuntary movements that mirror voluntary ones. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Mirror movements occur more commonly in the upper extremities. Some MRMV1 patients have agenesis of the corpus callosum.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
6.5 TPM
Brain Nucleus accumbens basal ganglia
2.8 TPM
Brain Caudate basal ganglia
2.3 TPM
Brain Frontal Cortex BA9
2.0 TPM
Hipotálamo
1.6 TPM
OUTRAS DOENÇAS (7)
colorectal cancermirror movements 1esophageal cancergaze palsy, familial horizontal, with progressive scoliosis, 2
HGNC:2701UniProt:P43146
IL17RDInterleukin-17 receptor DDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
MAP2K and MAPK activation
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 18 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
28.9 TPM
Cervix Ectocervix
15.1 TPM
Testículo
13.5 TPM
Cervix Endocervix
12.3 TPM
Fallopian Tube
11.9 TPM
OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 18 with or without anosmiaKallmann syndrome
HGNC:17616UniProt:Q8NFM7
HESX1Homeobox expressed in ES cells 1Disease-causing germline mutation(s) inTolerante
MECANISMO DE DOENÇA

Septooptic dysplasia

A clinically heterogeneous disorder defined by any combination of optic nerve hypoplasia, pituitary gland hypoplasia with panhypopopituitarism, and midline abnormalities of the brain, including absence of the corpus callosum and septum pellucidum.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
9.7 TPM
Linfócitos
4.2 TPM
Pituitária
2.4 TPM
Nervo tibial
2.3 TPM
Tireoide
2.3 TPM
OUTRAS DOENÇAS (5)
septooptic dysplasiaKallmann syndromehypothyroidism due to deficient transcription factors involved in pituitary development or functionpituitary stalk interruption syndrome
HGNC:4877UniProt:Q9UBX0
SOX10Transcription factor SOX-10Disease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (4)
EGR2 and SOX10-mediated initiation of Schwann cell myelinationRegulation of CDH19 Expression and FunctionTranscriptional and post-translational regulation of MITF-M expression and activityRegulation of MITF-M-dependent genes involved in pigmentation
MECANISMO DE DOENÇA

Waardenburg syndrome 2E

An autosomal dominant auditory-pigmentary disorder characterized by sensorineural deafness, pigmentary disturbances of the hair, skin and eyes, and absence of dystopia canthorum which is the lateral displacement of the inner canthus of each eye. Individuals with WS2E may have neurologic abnormalities, including mental impairment, myelination defects, and ataxia. Some patients can manifest features of Kallmann syndrome.

OUTRAS DOENÇAS (6)
Waardenburg syndrome type 4CWaardenburg syndrome type 2EPCWH syndromeKallmann syndrome
HGNC:11190UniProt:P56693
FEZF1Fez family zinc finger protein 1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 22 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
6.3 TPM
Hipotálamo
4.5 TPM
Brain Caudate basal ganglia
2.2 TPM
Cérebro - Amígdala
1.7 TPM
Brain Putamen basal ganglia
1.4 TPM
OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 22 with or without anosmiaKallmann syndrome
HGNC:22788UniProt:A0PJY2
PROKR2Prokineticin receptor 2Disease-causing germline mutation(s) (loss of function) inTolerante
VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 3 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
0.7 TPM
Brain Frontal Cortex BA9
0.3 TPM
Córtex cerebral
0.2 TPM
Brain Anterior cingulate cortex BA24
0.1 TPM
Hipocampo
0.1 TPM
OUTRAS DOENÇAS (5)
hypogonadotropic hypogonadism 3 with or without anosmiapituitary stalk interruption syndromeKallmann syndromehypogonadotropic hypogonadism
HGNC:15836UniProt:Q8NFJ6
ANOS1Anosmin-1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (2)
FGFR1c ligand binding and activationNegative regulation of FGFR1 signaling
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 1 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 1 with or without anosmiaKallmann syndrome
HGNC:6211UniProt:P23352
FGFR1Fibroblast growth factor receptor 1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (2)
Epithelial-Mesenchymal Transition (EMT) during gastrulationFormation of paraxial mesoderm
MECANISMO DE DOENÇA

Pfeiffer syndrome

A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
144.8 TPM
Ovário
142.9 TPM
Artéria tibial
134.1 TPM
Fallopian Tube
122.3 TPM
Cérebro - Hemisfério cerebelar
122.0 TPM
OUTRAS DOENÇAS (20)
Hartsfield-Bixler-Demyer syndromeencephalocraniocutaneous lipomatosisosteoglophonic dysplasiaPfeiffer syndrome
HGNC:3688UniProt:P11362
TACR3Neuromedin-K receptorDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsTachykinin receptors bind tachykinins
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 11 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Baixa expressão)
Hipotálamo
1.3 TPM
Bladder
1.2 TPM
Brain Spinal cord cervical c-1
0.5 TPM
Substância negra
0.4 TPM
Cérebro - Amígdala
0.4 TPM
OUTRAS DOENÇAS (3)
hypogonadotropic hypogonadism 11 with or without anosmiaKallmann syndromehypogonadotropic hypogonadism
HGNC:11528UniProt:P29371
SEMA3ASemaphorin-3ADisease-causing germline mutation(s) (loss of function) inAltamente restrito
VIAS BIOLÓGICAS (3)
Sema3A PAK dependent Axon repulsionSEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesionCRMPs in Sema3A signaling
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 16 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Tecido-específico)
Cólon sigmoide
14.5 TPM
Esôfago - Muscular
13.6 TPM
Esôfago - Junção
13.2 TPM
Bladder
7.0 TPM
Cólon transverso
4.9 TPM
OUTRAS DOENÇAS (3)
Kallmann syndromeBrugada syndromehypogonadotropic hypogonadism 16 with or without anosmia
HGNC:10723UniProt:Q14563
FLRT3Leucine-rich repeat transmembrane protein FLRT3Disease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (2)
Downstream signaling of activated FGFR1Signaling by ROBO receptors
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 21 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
15.2 TPM
Cérebro - Hemisfério cerebelar
13.7 TPM
Rim - Medula
12.8 TPM
Cerebelo
10.7 TPM
Próstata
10.2 TPM
OUTRAS DOENÇAS (2)
hypogonadotropic hypogonadism 21 with or without anosmiaKallmann syndrome
HGNC:3762UniProt:Q9NZU0
PROK2Prokineticin-2Disease-causing germline mutation(s) (loss of function) inTolerante
VIAS BIOLÓGICAS (2)
G alpha (q) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 4 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
210.0 TPM
Baço
30.0 TPM
Testículo
18.9 TPM
Pulmão
13.6 TPM
Adipose Visceral Omentum
1.7 TPM
OUTRAS DOENÇAS (3)
hypogonadotropic hypogonadism 4 with or without anosmiahypogonadotropic hypogonadismKallmann syndrome
HGNC:18455UniProt:Q9HC23
CCDC141Coiled-coil domain-containing protein 141Major susceptibility factor inTolerante
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
Kallmann syndrome
HGNC:26821UniProt:Q6ZP82
WDR11WD repeat-containing protein 11Disease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (1)
RHOH GTPase cycle
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
30.5 TPM
Linfócitos
29.9 TPM
Nervo tibial
28.9 TPM
Útero
28.5 TPM
Cervix Ectocervix
28.3 TPM
OUTRAS DOENÇAS (5)
intellectual developmental disorder, autosomal recessive 78hypogonadotropic hypogonadism 14 with or without anosmiaKallmann syndromehypogonadotropic hypogonadism
HGNC:13831UniProt:Q9BZH6
SPRY4Protein sprouty homolog 4Disease-causing germline mutation(s) inModerado
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 17 with or without anosmia

A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
54.9 TPM
Artéria coronária
51.1 TPM
Pulmão
46.7 TPM
Adipose Visceral Omentum
44.7 TPM
Tireoide
38.7 TPM
OUTRAS DOENÇAS (4)
hypogonadotropic hypogonadism 17 with or without anosmiahypogonadotropic hypogonadismKallmann syndrometesticular non-seminomatous germ cell tumor
HGNC:15533UniProt:Q9C004

Variantes genéticas (ClinVar)

4.118 variantes patogênicas registradas no ClinVar.

🧬 CHD7: NM_017780.4(CHD7):c.6367T>G (p.Ser2123Ala) ()
🧬 CHD7: NM_017780.4(CHD7):c.1467A>G (p.Gln489=) ()
🧬 CHD7: NM_017780.4(CHD7):c.8727A>G (p.Leu2909=) ()
🧬 CHD7: NM_017780.4(CHD7):c.3522+4T>A ()
🧬 CHD7: NM_017780.4(CHD7):c.2097-15del ()
Ver todas no ClinVar

Vias biológicas (Reactome)

67 vias biológicas associadas aos genes desta condição.

MITF-M and the SWI/SNF complex bind the TYR promoter Peptide ligand-binding receptors G alpha (q) signalling events HS-GAG biosynthesis PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR3b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling RAF-independent MAPK1/3 activation ERKs are inactivated Negative regulation of MAPK pathway Signaling by MAPK mutants Netrin-1 signaling DSCAM interactions DCC mediated attractive signaling Netrin mediated repulsion signals Caspase activation via Dependence Receptors in the absence of ligand Role of second messengers in netrin-1 signaling Regulation of commissural axon pathfinding by SLIT and ROBO MAP2K and MAPK activation EGR2 and SOX10-mediated initiation of Schwann cell myelination Regulation of CDH19 Expression and Function Regulation of MITF-M-dependent genes involved in pigmentation Transcriptional and post-translational regulation of MITF-M expression and activity Signaling by FGFR1 amplification mutants FGFR1b ligand binding and activation FGFR1c and Klotho ligand binding and activation NCAM signaling for neurite out-growth Signal transduction by L1 Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by plasma membrane FGFR1 fusions Epithelial-Mesenchymal Transition (EMT) during gastrulation Formation of paraxial mesoderm Tachykinin receptors bind tachykinins Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling Signaling by ROBO receptors RHOH GTPase cycle

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado3
2Fase 22
1Fase 15
·Pré-clínico12
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 22 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Kallmann

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 3 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

22 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
NCT04733274 · Patient and Healthcare Professional Views on Genetic/Genomic…Ativo
🇺🇸 Estados Unidos
NCT05971836 · The Molecular Basis of Inherited Reproductive DisordersConcluído
🇺🇸 Estados Unidos
NCT01914172 · Health Needs of Patients With Kallmann SyndromeConcluído
🇨🇭 Suíça
NCT01438034 · Kisspeptin in the Evaluation of Delayed PubertyConcluído
PHASE1🇺🇸 Estados Unidos
NCT01511588 · Hormonal Regulation of Puberty and FertilityConcluído
🇺🇸 Estados Unidos
NCT01403532 · Sequential Therapy for Hypogonadotropic HypogonadismConcluído
PHASE4🇨🇳 China
NCT00914823 · Kisspeptin Administration in the AdultConcluído
PHASE1🇺🇸 Estados Unidos
NCT00470990 · Effect of Varying Testosterone Levels on Insulin Sensitivity…Concluído
NA🇺🇸 Estados Unidos
NCT00494169 · Investigation of the Genetic Causes of Kallmann Syndrome and…Concluído
🇺🇸 Estados Unidos
NCT00493961 · Studying the Effects of 7 Days of Gonadotropin Releasing Hor…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00392457 · Investigating the Regulation of Reproductive Hormones in Adu…Concluído
NA🇺🇸 Estados Unidos
NCT00392756 · Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH…Concluído
PHASE1🇺🇸 Estados Unidos
NCT03687606 · Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG …UNKNOWN
PHASE4🇨🇳 China
NCT02880280 · Human Menopausal Gonadotropin Combining With Human Chorionic…UNKNOWN
PHASE4🇨🇳 China
NCT00623116 · A Study to Characterize Epidemiology, Clinical and Genetic F…UNKNOWN
NA🇫🇮 Finlândia
NCT00456274 · Baselines in Reproductive DisordersUNKNOWN
NA🇺🇸 Estados Unidos
NCT00383656 · Pulsatile GnRH in Anovulatory InfertilityUNKNOWN
PHASE2🇺🇸 Estados Unidos
NCT02356172 · Psychological Outcomes in Isolated GnRH DeficiencyEncerrado
🇺🇸 Estados Unidos
NCT03118479 · Effect of Varying Testosterone Levels on Insulin Sensitivity…Encerrado
PHASE1🇺🇸 Estados Unidos
NCT00064987 · Follicle Stimulating Hormone (FSH) to Improve Testicular Dev…Encerrado
PHASE2🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Meta-análise
Timeline de publicações
442 papers (10 anos)
#1

[Kallmann syndrome in a girl caused by a novel CHD7 variant].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026 Feb 15

This article reports the case of a 15-year-old girl with primary amenorrhea and olfactory dysfunction. Evaluation demonstrated hypogonadotropic hypogonadism, and an initial clinical diagnosis of Kallmann syndrome was made. Whole-exome sequencing identified a novel heterozygous CHD7 variant, c.5238_5239del(p.Tyr1746*), which was classified as likely pathogenic according to the variant interpretation guidelines of the American College of Medical Genetics and Genomics. In light of the typical clinical phenotype and genetic findings, the patient was diagnosed with CHD7-related Kallmann syndrome. This case broadens the CHD7 mutational spectrum in Kallmann syndrome and provides valuable insights to inform clinicians' understanding of this disease. 患儿,女,15岁,因原发性闭经,伴有嗅觉障碍就诊。完善检查提示为低促性腺激素性性腺功能减退症,初步诊断为Kallmann综合征。经全外显子组测序发现患儿存在CHD7基因c.5238_5239del(p.Tyr1746*)新发杂合变异,依据美国医学遗传学与基因组学学会变异解读指南,该变异为疑似致病变异。结合典型临床表现,该患儿确诊为CHD7基因杂合变异所致的Kallmann综合征。该病例丰富了Kallmann综合征基因变异谱,为临床医生对该病的认识提供参考。.

#2

Clinical and genetic basis of congenital gonadotropin deficiency.

Human reproduction open2026

What is the clinical and genetic overlap across subtypes of congenital gonadotropin (Gn) deficiency? This study reveals substantial clinical and genetic overlap among Gn deficiency disorders, with shared genetic and developmental features across congenital hypogonadotropic hypogonadism (CHH), combined pituitary hormone deficiency (CPHD), and syndromic forms of Gn deficiency. Congenital Gn deficiency includes a subset of hypogonadotropic hypogonadism (HH) and can result from defects at the level of the hypothalamus or the pituitary. It includes (i) CHH, further classified into normosmic CHH (nCHH) and Kallmann syndrome (KS); (ii) CPHD; and (iii) syndromic forms such as CHARGE syndrome and septo-optic dysplasia (SOD). The study included all probands with Gn deficiency recruited at a tertiary care center between 2011 and 2024 (n = 568), including 276 KS, 247 nCHH, 29 CPHD, and 16 syndromic Gn deficiency cases. All individuals underwent detailed clinical phenotyping followed by DNA sequencing. Genetic analysis focused on pathogenic (P) and likely pathogenic (LP) variants and variants of uncertain significance (VUS) within established CHH and CPHD genes. Oligogenicity was assessed in the CHH/syndromic HH cohort (n = 523) compared with controls from 1000 Genomes (n = 601). Genetic overlap among CHH, CPHD, and syndromic Gn deficiency was systematically investigated. Cleft lip/palate, dental agenesis, and ear abnormalities were recurrent across all Gn-deficient groups. Notably, some CPHD and SOD patients exhibited anosmia and a preserved Gn response to LH-releasing hormone (LHRH) stimulation, indicating a hypothalamic component to their HH. Rare variants in CHH genes were identified in 53% of KS probands (40% P/LP, 13% VUS) and 33% of nCHH probands (23% P/LP, 10% VUS). FGFR1, ANOS1, and PROKR2 were most frequently mutated in KS, while GNRHR, FGFR1, and KISS1R predominated in nCHH. Oligogenic inheritance was detected in 15% of CHH cases, with variants in FGFR1 being most commonly involved. Importantly, a substantial proportion (14%) of CHH patients without a molecular diagnosis carried rare variants predicted to be P or LP in genes typically associated with CPHD (e.g. ROBO1, BRAF, FAT2, and DCHS2). Conversely, several CHH-associated genes such as FGFR1 and FGF8, already implicated in CPHD, were also identified in patients with CPHD and syndromic GN deficiency, further supporting a shared genetic architecture between CHH and CPHD. N/A. Non-coding and copy number variants were not studied. Functional studies of the new candidate genes for CHH were not undertaken. This study highlights the importance of comprehensive clinical evaluation and broadened genetic testing in patients with Gn deficiency. This work was supported by the Swiss National Foundation (NP) (Grant No. 310030B_201275 to N.P.) and the Natural Science Foundation of Beijing (Grant No. 7244338 to Y.W.). The authors declare no competing interests.

#3

From patients to partners: Evaluating a co-designed website for congenital hypogonadotropic hypogonadism.

Endocrine connections2026 Mar 20

Patients with congenital hypogonadotropic hypogonadism (CHH) are geographically dispersed and have unmet health and informational needs. Patients often rely on the internet to learn about CHH, find expert care, and connect with other patients. We partnered with patients to co-design a website (virtual empowerment toolkit) and conducted an online evaluation of the website. Healthcare providers, patients, and a design team engaged in an iterative 'design thinking' process (i.e., empathize, define, ideate, prototype, refine, test) to co-design the website. Subsequently, patients with CHH were recruited and evaluated the site using the 'gold standard' Patient Education Materials Assessment Tool for audio/visual materials (PEMAT-A/V). Scores ≥80% on PEMAT-A/V domains are considered 'high-quality'. Content analysis was used to group qualitative feedback into salient themes. Patients were involved from the outset and in all stages of the design thinking process. Iterative patient focus groups and online surveys were used to prioritize content and refine prototypes. In total, 58 participants (48.5±14.4 yrs.) completed the online evaluation. All PEMAT-A/V domains scored >88% (i.e., 'high-quality'). Participants (47/55, 86%) rated the site 'easy to navigate' and 52/55 (95%) would recommend the site to another patient. Qualitative feedback was largely positive and expressed appreciation for the online resource. Partnering with patients to co-design the virtual patient empowerment toolkit produced an understandable, actionable website that was responsive to patient priorities. This work supports the utility of co-creation and co-design for empowering patients with CHH and may serve as a roadmap for other rare diseases.

#4

Genetic Basis and Heterogeneity of Congenital Hypogonadotropic Hypogonadism.

Seminars in reproductive medicine2026 Mar 02

Congenital hypogonadotropic hypogonadism (CHH) is a rare genetic disorder characterized by absent or incomplete pubertal development due to impaired production, secretion, or action of gonadotropin-releasing hormone (GnRH). When associated with anosmia or hyposmia, it is termed Kallmann syndrome. CHH exhibits striking clinical and genetic heterogeneity, encompassing either sporadic or familial cases, with inheritance patterns that include X-linked, autosomal dominant, and autosomal recessive transmission. Over the past few decades, major advances uncovered the molecular basis of CHH, shedding light on the intricate neuroendocrine regulation of human reproduction. A growing repertoire of genes has been implicated in CHH molecular pathogenesis, encoding proteins involved in the ontogeny and function of GnRH neurons. Notably, pathogenic variants in genes typically associated with complex syndromes have also been identified in patients with isolated CHH or subtle syndromic manifestations, suggesting a wide spectrum of expressivity and incomplete penetrance. Furthermore, spontaneous hypogonadism reversal, either permanent or temporary, may occur in some patients, suggesting a potential neuroplasticity within the GnRH neuronal network. This review summarizes recent advances in the molecular genetics of CHH, emphasizing the expanding spectrum of causative genes and their inheritance patterns. · Congenital hypogonadotropic hypogonadism (CHH) is a rare reproductive disorder caused by impaired production, secretion, or action of gonadotropin-releasing hormone (GnRH). When CHH is associated with olfactory defects (hyposmia or anosmia), it is termed Kallmann syndrome.. · CHH is a complex clinical and genetic heterogeneous condition with both sporadic and familial cases. Inheritance can be X-linked, autosomal recessive, or dominant.. · Although more than 60 genes have been implicated in the molecular pathogenesis of CHH, approximately 50% of cases remain without molecular diagnosis.. · CHH-associated genes encode proteins involved either in GnRH neuron ontogeny and migration or in GnRH synthesis, secretion, or action.. · Digenic or oligogenic inheritance accounts for up to 20% of CHH cases and may explain the high phenotypic variability observed among affected families.. · Pathogenic variants in genes associated with complex syndromes have been identified in cases of isolated CHH or in cases with only one additional phenotypic feature, resembling mild or incomplete forms of the original syndrome.. · Spontaneous recovery of reproductive function may occur in 10 to 20% of patients with CHH, including those harboring rare pathogenic variants in typical CHH-associated genes..

#5

Congenital Hypogonadotropic Hypogonadism Caused by Prokineticin Receptor 2 Rare Sequence Variants: Molecular Genetics, Clinical Phenotypes and Therapeutic Outcomes From a Single-center Cohort.

Andrology2026 Feb 25

Limited data are available regarding the fertility-inducing treatment outcomes and spermatogenic duration in congenital hypogonadotropic hypogonadism patients carrying prokineticin receptor 2 rare sequence variants. We aimed to delineate the rare sequence variant profiles of PROKR2 in a large Chinese cohort with congenital hypogonadotropic hypogonadism, and to characterize the associated clinical phenotypes and therapeutic outcomes. In addition, the reproductive phenotypes and therapeutic outcomes were compared between patients with congenital hypogonadotropic hypogonadism who harbored PROKR2 rare sequence variants and those without identified rare sequence variants in known congenital hypogonadotropic hypogonadism-associated genes. Seven unrelated congenital hypogonadotropic hypogonadism probands carrying PROKR2 rare sequence variants (four with Kallmann syndrome and three with normosmic congenital hypogonadotropic hypogonadism) were included. PROKR2 variants in these patients were identified using targeted next-generation sequencing and verified using Sanger sequencing. The pathogenicity of the identified PROKR2 rare sequence variants was assessed according to the American College of Medical Genetics and Genomics guidelines. Baseline clinical characteristics and therapeutic outcomes were retrospectively evaluated and compared between patients with PROKR2 rare sequence variants and those lacking the identified rare sequence variants in established congenital hypogonadotropic hypogonadism-associated genes. We identified a novel PROKR2 rare sequence variant (p.Y154*, a nonsense mutation). Four rare sequence variants were classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines. Spermatogenesis was achieved in all six male patients with PROKR2 rare sequence variants who received gonadotropin therapy following an average of 1.28 years. No statistically significant differences were observed in the baseline clinical characteristics and spermatogenic outcomes between patients with PROKR2 rare sequence variants and those without identified rare sequence variants in known congenital hypogonadotropic hypogonadism-associated genes. We observed a lack of evidence for a significant difference in reproductive phenotype or spermatogenic outcomes between male patients with congenital hypogonadotropic hypogonadism and PROKR2 rare sequence variants and those without identified rare sequence variants in congenital hypogonadotropic hypogonadism-associated genes, but this finding is critically limited by the small number of PROKR2 rare sequence variant carriers in our treatment cohort. The identification of a novel PROKR2 rare sequence variant expands the PROKR2 variant spectrum in patients with congenital hypogonadotropic hypogonadism.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC442 artigos no totalmostrando 200

2026

Clinical and genetic basis of congenital gonadotropin deficiency.

Human reproduction open
2026

From patients to partners: Evaluating a co-designed website for congenital hypogonadotropic hypogonadism.

Endocrine connections
2026

Genetic Basis and Heterogeneity of Congenital Hypogonadotropic Hypogonadism.

Seminars in reproductive medicine
2026

[Kallmann syndrome in a girl caused by a novel CHD7 variant].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2026

Congenital Hypogonadotropic Hypogonadism Caused by Prokineticin Receptor 2 Rare Sequence Variants: Molecular Genetics, Clinical Phenotypes and Therapeutic Outcomes From a Single-center Cohort.

Andrology
2025

A rare case of Kallmann syndrome in a female with pulmonary valve stenosis: Coincidence or genetic link?

La Tunisie medicale
2026

Kallmann Syndrome in a 30-Year-Old Female With Primary Infertility: A Case Report.

Case reports in obstetrics and gynecology
2025

Association of self-stigma, impulsivity, and insomnia with anxiety and depression in patients with Kallmann syndrome.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2026

Overestimation of Pathogenic Variants in Idiopathic Hypogonadotropic Hypogonadism and Kallmann Syndrome.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2026

Association of increased cortical thickness and cognitive impairment in patients with Kallmann syndrome.

European journal of endocrinology
2025

Case Report: Diabetic ketoacidosis in a patient with Klinefelter syndrome: a rare and complex presentation.

Frontiers in endocrinology
2026

Pregnancy in a woman with Kallmann-De Morsier syndrome: A case report.

Clinical and experimental reproductive medicine
2026

Identification and Functional Characterization of a Novel SEMA3A Exon Deletion Variant in Kallmann Syndrome.

Molecular genetics &amp; genomic medicine
2026

A young woman with Kallmann syndrome and acute neurologic symptoms.

Cleveland Clinic journal of medicine
2026

The prevalence of pathogenic variants in medically actionable genes among individuals with idiopathic hypogonadotropic hypogonadism/Kallmann syndrome.

Journal of assisted reproduction and genetics
2025

Clinical approach to the male with delayed puberty.

Archives of endocrinology and metabolism
2025

Functional Validation and Phenotypic Spectrum of Splice-Site Variants in CHD7, FGFR1, and ANOS1 in Congenital Hypogonadotropic Hypogonadism.

Clinical genetics
2025

Metabolic sexual dimorphism in hypothalamic Fezf1 neuron-specific BDNF knockout.

Biology of sex differences
2026

Reversal of Congenital Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2025

A familial case of Kallmann syndrome: novel variants in ANOS1 and GNRHR genes.

Archives of endocrinology and metabolism
2025

Chromosomal Roadblocks in Male Fertility: Mechanisms, Risk Factors and Syndromes.

Medicina (Kaunas, Lithuania)
2025

Mirror Movements and Ichthyosis in a Child: A Rare Presentation of Kallmann Syndrome.

Annals of Indian Academy of Neurology
2025

FGFR1-related congenital hypogonadotropic hypogonadism: a case report and literature review.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
2026

Body Composition by DXA in Patients with Klinefelter and Kallmann Syndrome: The Kama Study.

The Journal of clinical endocrinology and metabolism
2025

Incomplete Evidence of Bone Density Normalization Following Long-Term Reproductive Hormone Treatment in Men With Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2025

Sperm DNA methylation profiling in patients with Kallmann syndrome.

Endocrine connections
2025

Genetics of Idiopathic Hypogonadotropic Hypogonadism.

Journal of clinical research in pediatric endocrinology
2025

Gender Dysphoria and Transition in a Patient with Kallmann Syndrome: A Case Report.

LGBT health
2026

Expanded Targeted-Exome Sequencing and Functional Validation Improve Molecular Diagnosis and Refine Genotype-Phenotype Correlations in Congenital Hypogonadotropic Hypogonadism.

Neuroendocrinology
2025

Modification of the Sniffin Kids Test for olfactory testing in a population of Polish children.

Rhinology
2025

The Lysine at Position 177 Is Essential to Limit the Inhibitory Capacities of Sprouty4 Protein in Normal and Cancer-Derived Cells.

International journal of molecular sciences
2025

Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study.

Translational andrology and urology
2025

Spatiotemporal regulation by downstream genes of Prok2 in the olfactory system: from development to function.

Frontiers in cell and developmental biology
2025

Spontaneous Improvement of Hypogonadotropic Hypogonadism in a Patient with PCSK1 and HS6ST1 Mutations: A Case Report.

Life (Basel, Switzerland)
2025

Altered glucose metabolism in default mode network and prefrontal circuit in patients with Kallmann syndrome.

EJNMMI research
2025

De Novo Splice Site Variant of TCF12 in a Boy With Isolated Kallmann Syndrome.

Case reports in endocrinology
2025

Identification of Novel Genetic Variants in a Cohort of Congenital Hypogonadotropic Hypogonadism: Computational Analysis of Pathogenicity Predictions.

International journal of molecular sciences
2025

Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study.

Human reproduction open
2025

A rare combination of hypogonadotropic hypogonadism, GH deficiency and rectal atresia in a female with an FGFR1 variant: a case report and systematic review of the literature.

Endocrine
2025

Intrafamilial Phenotypic Variability of the FGFR1 p.Cys277Tyr Variant: A Case Report and Review of the Literature.

Genes
2025

Pluripotent Stem Cell Plasticity is Sculpted by a Slit-Independent Robo Pathway in a Regenerative Animal.

bioRxiv : the preprint server for biology
2025

Health Disparities and Disrupted Puberty in Males.

Endocrinology and metabolism clinics of North America
2025

Worth the Effort: Lessons for Discovery and Care From an Unusual Case of Gorlin Syndrome.

American journal of medical genetics. Part A
2025

Kallmann Syndrome due to Balanced X Chromosomal Pericentric Inversion Disrupting ANOS1.

Cytogenetic and genome research
2025

Two cases of Kallmann syndrome caused by a novel mutation in ANOS1: A case report.

Medicine
2025

Involvement of a Novel Variant of FGFR1 Detected in an Adult Patient with Kallmann Syndrome in Regulation of Gonadal Steroidogenesis.

International journal of molecular sciences
2025

An Effective Outcome Despite Delayed Treatment Initiation in a Female With Kallmann Syndrome: A Case Report.

Cureus
2025

PROKR2 mutations and SPRY4 variants with uncertain significance in a Kallmann syndrome family: Incomplete penetrance.

Global medical genetics
2025

Co-occurrence of a Mullerian anomaly and Kallmann syndrome: A case report.

Case reports in women's health
2025

Phenotype and genotype of 23 patients with hypopituitarism and pathogenic GLI2 variants.

European journal of endocrinology
2025

Oral and Maxillofacial Manifestations of Kallmann Syndrome: A Systematic Analysis of the Literature.

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
2025

Magnetic resonance imaging does not distinguish Kallmann syndrome from normosmic isolated hypogonadotropic hypogonadism.

Endocrine connections
2025

Autosomally dominantly inherited isolated gonadotropin deficiency via maternal assisted reproduction due to SOX10 mutation.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2024

Kallmann Syndrome: Functional Analysis of a CHD7 Missense Variant Shows Aberrant RNA Splicing.

International journal of molecular sciences
2025

Hypogonadotropic hypogonadism as a cause of NOA and its treatment.

Asian journal of andrology
2024

Genetic Polymorphisms of Prokineticins and Prokineticin Receptors Associated with Human Disease.

Life (Basel, Switzerland)
2024

Hypogonadotropic Hypogonadism as First Presentation of the Severe Neuroendocrine Disorder Caused by RNF216.

JCEM case reports
2025

Cribriform Plate Foramina Count in Patients With Acquired and Congenital Anosmia.

American journal of rhinology &amp; allergy
2025

A closer look: sperm analysis and clinical outcomes of microscopic and loupe-assisted varicocele repair in male infertility due to moderate-to-severe varicocele.

International urology and nephrology
2025

Kallmann syndrome: Diagnostics and management.

Clinica chimica acta; international journal of clinical chemistry
2024

Fgf17: A regulator of the mid/hind brain boundary in mammals.

Differentiation; research in biological diversity
2024

DNA methylation changes in the genome of patients with hypogonadotropic hypogonadism.

Heliyon
2024

Genetic architecture of congenital hypogonadotropic hypogonadism: insights from analysis of a Portuguese cohort.

Human reproduction open
2024

Diagnosis of Kallmann Syndrome in a Young Adult Male.

Cureus
2024

Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism.

Annals of the New York Academy of Sciences
2024

Genetic Variability of SOX10-Related Disorders within an Italian Family: Straddling the Line between Kallmann and Waardenburg Syndrome.

Molecular syndromology
2024

Case report: An adolescent female with anosmic hypogonadotropic hypogonadism, intellectual disability, and papillary thyroid carcinoma: heterozygous deletion of TCF12.

Frontiers in endocrinology
2024

Deletion in RMST lncRNA impairs hypothalamic neuronal development in a human stem cell-based model of Kallmann Syndrome.

Cell death discovery
2024

Indications for genetic diagnosis in children with growth hormone deficiency and born small for gestational age.

Pediatric endocrinology, diabetes, and metabolism
2024

Gonadotropin treatment of cryptorchidism in congenital hypogonadotropic hypogonadism-Age is no limit?

Clinical endocrinology
2024

46 XX Ovotesticular Disorder of Sex Development with Gonadotropin-Releasing Hormone Receptor, Autosomal Recessive Heterozygous Missense Mutation and Autosomal Dominant Heterozygous Missense Mutation of the PROKR2 Gene: A Case Report.

Global medical genetics
2024

Combined gonadotropin therapy to replace mini-puberty in male infants with congenital hypogonadotropic hypogonadism.

Annals of the New York Academy of Sciences
2024

Hypogonadotropic hypogonadism with Zinner syndrome: a coincidence or a consequence?

BMJ case reports
2024

A novel mutation in ANOS1 in a Chinese family with Kallmann syndrome: Case report.

Clinical case reports
2024

Unusual coexistence of restrictive heart disease and Kallmann syndrome: a case report.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology
2024

Clinical phenotype of a Kallmann syndrome patient with IL17RD and CPEB4 variants.

Frontiers in endocrinology
2024

Smelling TNT: Trends of the Terminal Nerve.

International journal of molecular sciences
2024

Prevalence of pathogenic variants and digenic disease in patients diagnosed with normosmic hypogonadotropic hypogonadism/Kallmann Syndrome.

Molecular and cellular endocrinology
2024

Fertility outcomes in male adults with congenital hypogonadotropic hypogonadism treated during puberty with human chorionic gonadotropin and recombinant follicle stimulating hormone.

Journal of paediatrics and child health
2024

Case report: Novel SIN3A loss-of-function variant as causative for hypogonadotropic hypogonadism in Witteveen-Kolk syndrome.

Frontiers in genetics
2024

Illuminating the terminal nerve: Uncovering the link between GnRH-1 neuron and olfactory development.

The Journal of comparative neurology
2024

Contributions of Common Genetic Variants to Constitutional Delay of Puberty and Idiopathic Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2024

Mini-Puberty, Physiological and Disordered: Consequences, and Potential for Therapeutic Replacement.

Endocrine reviews
2024

Additional mutation in PROKR2 and phenotypic differences in a Kallmann syndrome/normosmic congenital hypogonadotropic hypogonadism family carrying FGFR1 missense mutation.

BMJ case reports
2024

The "Sniffin' Kids-PT" test: A smell test variant for Portuguese children.

European annals of otorhinolaryngology, head and neck diseases
2024

Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.

European journal of endocrinology
2024

Outcomes and experiences of adults with congenital hypogonadism can inform improvements in the management of delayed puberty.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2023

Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia.

Frontiers in endocrinology
2023

What Are the Best Practices for Co-Creating Patient-Facing Educational Materials? A Scoping Review of the Literature.

Healthcare (Basel, Switzerland)
2023

Clinical and molecular features of 40 Chinese patients with idiopathic hypogonadotropic hypogonadism.

Translational andrology and urology
2023

Bibliometric analysis of scientific publications on cryptorchidism: Research hotspots and trends between 2000 and 2022.

Heliyon
2023

Clinical Manifestations, Genetic Variants and Therapeutic Evaluation in Sporadic Chinese Patients with Idiopathic Hypogonadotropic Hypogonadism.

International journal of general medicine
2023

Idiopathic hypogonadotropic hypogonadism caused by compound heterozygosity for two novel mutations in the GNRH1 gene: a case report.

BMC endocrine disorders
2024

Mixed hypogonadism: a neglected combined form of hypogonadism.

Endocrine
2023

Key features of puberty onset and progression can help distinguish self-limited delayed puberty from congenital hypogonadotrophic hypogonadism.

Frontiers in endocrinology
2023

Illuminating the Terminal Nerve: Uncovering the Link between GnRH-1 and Olfactory Development.

bioRxiv : the preprint server for biology
2023

CHD7 variants associated with hearing loss and enlargement of the vestibular aqueduct.

Human genetics
2023

Congenital hypogonadotropic hypogonadism in a patient with a de novo POGZ mutation.

European journal of endocrinology
2023

Pubertal induction with gonadotropins in an adult male with Kallmann syndrome.

Medicina clinica
2023

A cryptic microdeletion del(12)(p11.21p11.23) within an unbalanced translocation t(7;12)(q21.13;q23.1) implicates new candidate loci for intellectual disability and Kallmann syndrome.

Scientific reports
2023

Coordination of canonical and noncanonical Hedgehog signalling pathways mediated by WDR11 during primordial germ cell development.

Scientific reports
2023

From Nose to Lumbar Spinal Cord - Reduced Sperm Numbers Occur by Olfactory Bulbectomy-Related Onuf's Nucleus Degeneration: New Experimental Evidence for Kallmann Syndrome.

Neuroendocrinology
2023

Congenital hypogonadotrophic hypogonadism, induction of minipuberty, and future fertility.

Endocrinology, diabetes &amp; metabolism case reports
2023

[Olfactory function and olfactory bulbs in patients with Kallmann syndrome].

Problemy endokrinologii
2023

[Missense mutation of SPRY4 gene in Kallmann syndrome: a case report].

Zhonghua nei ke za zhi
2023

Alteration of replication protein A binding mode on single-stranded DNA by NSMF potentiates RPA phosphorylation by ATR kinase.

Nucleic acids research
2023

Digenic Congenital Hypogonadotropic Hypogonadism Due to Heterozygous GNRH1 p.R31C and AMHR2 p.G445_L453del Variants.

Genes
2023

A clinical case of identical twins with hypogonadotropic hypogonadism, primary empty sella syndrome and identified rare CHD7 gene variant.

Clinical case reports
2023

A case of novel mutation in ANOS1 (KAL1) gene and review of Kallmann syndrome.

Endocrinology, diabetes &amp; metabolism case reports
2023

Genetic Analysis of Patients with Congenital Hypogonadotropic Hypogonadism: A Case Series.

International journal of molecular sciences
2023

A microdeletion del(12)(p11.21p11.23) with a cryptic unbalanced translocation t(7;12)(q21.13;q23.1) implicates new candidate loci for intellectual disability and Kallmann syndrome.

Research square
2024

Why Should Orchidopexy Be Performed in Congenital Hypogonadotropic Hypogonadism, and When?

Hormone research in paediatrics
2023

Case report: A case of Culler-Jones syndrome caused by a novel mutation of GLI2 gene and literature review.

Frontiers in endocrinology
2022

Diagnosis and genetic analysis of a case of Waardenburg syndrome type 2 with hypogonadotropic hypogonadism caused by SOX10 gene deletion.

Yi chuan = Hereditas
2023

Mutation spectrum and frequency of copy number variations of the ANOS1 gene in patients with Kallmann syndrome or normosmic isolated hypogonadotropic hypogonadism.

Endocrine connections
2023

Mutation spectrum of Kallmann syndrome: identification of five novel mutations across ANOS1 and FGFR1.

Reproductive biology and endocrinology : RB&amp;E
2023

[Male hypogonadotropic hypogonadism].

MMW Fortschritte der Medizin
2023

Phenotypic and genotypic landscape of PROKR2 in neuroendocrine disorders.

Frontiers in endocrinology
2023

[Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism].

Problemy endokrinologii
2023

Expanding the reproductive organ phenotype of CHD7-spectrum disorder.

American journal of medical genetics. Part A
2023

A novel missense variant of FGFR1 in a Japanese girl with Kallmann syndrome and holoprosencephaly.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2023

SIN3A Defects Associated with Syndromic Congenital Hypogonadotropic Hypogonadism: An Overlap with Witteveen-Kolk Syndrome.

Neuroendocrinology
2023

Defective jagged-1 signaling affects GnRH development and contributes to congenital hypogonadotropic hypogonadism.

JCI insight
2022

Sex differences in the coexpression of prokineticin receptor 2 and gonadal steroids receptors in mice.

Frontiers in neuroanatomy
2023

A rare disease of Kallmann syndrome: A case report.

Radiology case reports
2023

Reconsidering the olfactory and brain structures in Kallmann's syndrome: New findings in the analysis of volumetry.

Clinical endocrinology
2022

Insulin-like peptide 3 (INSL3) in congenital hypogonadotrophic hypogonadism (CHH) in boys with delayed puberty and adult men.

Frontiers in endocrinology
2022

A rare case of a 34-year-old patient diagnosed late with Kallmann syndrome: case report.

The Pan African medical journal
2023

Isolated Hypogonadotropic Hypogonadism: New Insights into Relationships Between Genotype and Reproductive Phenotype.

The Journal of clinical endocrinology and metabolism
2023

A novel homozygous nonsense NDNF variant in Kallmann syndrome.

American journal of medical genetics. Part A
2022

Reversible hypogonadotropic hypogonadism in men with the fertile eunuch/Pasqualini syndrome: A single-center natural history study.

Frontiers in endocrinology
2022

Research on the variants of FGFR1 and CEP290 genes in idiopathic hypogonadotropin hypogonadism.

Yi chuan = Hereditas
2022

[Analysis of a patient with Kallmann syndrome and a 45,X/46,XY karyotype].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2023

Reproductive Phenotypes and Genotypes in Men With IHH.

The Journal of clinical endocrinology and metabolism
2022

Identification and Functional Characterization of a Novel Variant in the SEMA3A Gene in a Chinese Family with Kallmann Syndrome.

International journal of endocrinology
2022

The Clinical and Genetic Characteristics in Children with Idiopathic Hypogonadotropin Hypogonadism.

Journal of oncology
2022

Treatment of congenital hypogonadotropic hypogonadism in male patients.

Annals of pediatric endocrinology &amp; metabolism
2022

The diagnostic value of the olfactory evaluation for congenital hypogonadotropic hypogonadism.

Frontiers in endocrinology
2022

X-linked recessive Kallmann syndrome: A case report.

World journal of clinical cases
2022

Genetic spectrum of Kallmann syndrome: Single-center experience and systematic review.

Clinical endocrinology
2022

Dynamic spectral signatures of mirror movements in the sensorimotor functional connectivity network of patients with Kallmann syndrome.

Frontiers in neuroscience
2022

Advancing qualitative rare disease research methodology: a comparison of virtual and in-person focus group formats.

Orphanet journal of rare diseases
2022

The great migration: How glial cells could regulate GnRH neuron development and shape adult reproductive life.

Journal of chemical neuroanatomy
2022

ANOS1 variants in a large cohort of Chinese patients with congenital hypogonadotropic hypogonadism.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2022

Identification of a novel mutation in FGFR1 gene in mother and daughter with Kallmann syndrome.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Congenital hypogonadotropic hypogonadism complicated by neuroblastoma.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2022

Convergent biological pathways underlying the Kallmann syndrome-linked genes Hs6st1 and Fgfr1.

Human molecular genetics
2022

Anosmin 1 N-terminal domains modulate prokineticin receptor 2 activation by prokineticin 2.

Cellular signalling
2022

Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls.

Cureus
2022

SLIT2 Rare Sequencing Variants Identified in Idiopathic Hypogonadotropic Hypogonadism.

Hormone research in paediatrics
2022

A rare case of congenital fibrosis of extra ocular muscles with Kallmann syndrome.

Indian journal of ophthalmology
2022

Exome Sequencing as a Tool for Detecting Point Mutations and Deletions in Patients With Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2022

Delayed Puberty Due to a WDR11 Truncation at Its N-Terminal Domain Leading to a Mild Form of Ciliopathy Presenting With Dissociated Central Hypogonadism: Case Report.

Frontiers in pediatrics
2022

Correlation Analysis of Genotypes and Phenotypes in Chinese Male Pediatric Patients With Congenital Hypogonadotropic Hypogonadism.

Frontiers in endocrinology
2022

Novel 12 Mb interstitial deletion of chromosome 8p11.22-p21.2: a case report.

BMC medical genomics
2022

Prevalence and Phenotypic Effects of Copy Number Variants in Isolated Hypogonadotropic Hypogonadism.

The Journal of clinical endocrinology and metabolism
2022

A Novel FGFR1 Missense Mutation in a Portuguese Family with Congenital Hypogonadotropic Hypogonadism.

International journal of molecular sciences
2022

Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study.

The Journal of clinical endocrinology and metabolism
2022

Exploring Rare Disease Patient Attitudes and Beliefs regarding Genetic Testing: Implications for Person-Centered Care.

Journal of personalized medicine
2022

Successful pregnancy and delivery after a vitrified-warmed embryo transfer in a woman with Kallmann syndrome: A case report and literature review.

Fukushima journal of medical science
2022

Unilaterally disrupted structural and functional connectivity of the fronto-limbic system in idiopathic hypogonadotropic hypogonadism.

Clinical endocrinology
2022

Biallelic PROKR2 variants and congenital hypogonadotropic hypogonadism: a case report and a literature review.

Endocrine journal
2022

Two Sisters with Kallmann Syndrome, Gonadal Dysgenesis, and Multiple Neuromuscular and Endocrine Disorders: Report of Two Cases with Description of an Unusual Association.

Reproductive sciences (Thousand Oaks, Calif.)
2022

PLXNB1 mutations in the etiology of idiopathic hypogonadotropic hypogonadism.

Journal of neuroendocrinology
2022

Hypertrophic pyloric stenosis masked by kidney failure in a male infant with a contiguous gene deletion syndrome at Xp22.31 involving the steroid sulfatase gene: case report.

Italian journal of pediatrics
2022

Clinical, hormonal, and genetic characteristics of 25 Chinese patients with idiopathic hypogonadotropic hypogonadism.

BMC endocrine disorders
2021

Molecular diagnosis of Kallmann syndrome with diabetes by whole exome sequencing and bioinformatic approaches.

World journal of diabetes
2022

Recent advancement in the treatment of boys and adolescents with hypogonadism.

Therapeutic advances in endocrinology and metabolism
2022

Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings.

Endocrine connections
2022

Current concepts surrounding neonatal hormone therapy for boys with congenital hypogonadotropic hypogonadism.

Expert review of endocrinology &amp; metabolism
2021

Kallmann Syndrome and X-linked Ichthyosis Caused by Translocation Between Chromosomes X and Y: A Case Report.

Journal of reproduction &amp; infertility
2022

When anorexia nervosa symptoms mask Kallmann syndrome.

Eating and weight disorders : EWD
2022

Genetics of congenital central hypogonadism.

Best practice &amp; research. Clinical endocrinology &amp; metabolism
2021

[Kalmann syndrome in monozygous twins as an isolated manifestation of the SOX10 gene defect].

Problemy endokrinologii
2022

SOX10: 20 years of phenotypic plurality and current understanding of its developmental function.

Journal of medical genetics
2021

TUBB3 Arg262His causes a recognizable syndrome including CFEOM3, facial palsy, joint contractures, and early-onset peripheral neuropathy.

Human genetics
2021

Analysis of PLXNA1, NRP1, and NRP2 variants in a cohort of patients with isolated hypogonadotropic hypogonadism.

Molecular genetics &amp; genomic medicine
2021

Diagnosis of Male Central Hypogonadism During Childhood.

Journal of the Endocrine Society
2021

A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis.

EMBO molecular medicine
2021

A novel heterozygous mutation of CHD7 gene in a Chinese patient with Kallmann syndrome: a case report.

BMC endocrine disorders
2021

Oligogenic Inheritance Underlying Incomplete Penetrance of PROKR2 Mutations in Hypogonadotropic Hypogonadism.

Frontiers in genetics
2021

[Molecular genetics and phenotypic features of congenital isolated hypogonadotropic hypogonadism].

Problemy endokrinologii
2021

The Differential Roles for Neurodevelopmental and Neuroendocrine Genes in Shaping GnRH Neuron Physiology and Deficiency.

International journal of molecular sciences
2021

Novel FGFR1 Variants Are Associated with Congenital Scoliosis.

Genes
2021

Seminal Plasma Lipidomics Profiling to Identify Signatures of Kallmann Syndrome.

Frontiers in endocrinology
2021

Mechanisms of Central Hypogonadism.

International journal of molecular sciences
2021

Two females presenting primary amenorrhea diagnosed with Kallmann syndrome caused by novel FGFR1 variants.

The journal of obstetrics and gynaecology research
2021

Slipped Capital Femoral Epiphysis in an Adult with Panhypopituitarism: A Case Report.

JBJS case connector
2021

[Clinical and molecular genetic features of cases of isolated hypogonadotropic hypogonadism, associated with defects in GNRHR genes].

Problemy endokrinologii
2021

Kallmann syndrome and idiopathic hypogonadotropic hypogonadism: The role of semaphorin signaling on GnRH neurons.

Handbook of clinical neurology
2022

Diagnostic yield of clinical exome sequencing in congenital hypogonadotropic hypogonadism considering the degree of olfactory impairment.

Anales de pediatria
2022

A Novel Noncanonical Splicing Mutation of ANOS1 Gene in Siblings with Kallmann Syndrome Identified by Whole-Exome Sequencing.

Reproductive sciences (Thousand Oaks, Calif.)
2022

Advances in Genetic Diagnosis of Kallmann Syndrome and Genetic Interruption.

Reproductive sciences (Thousand Oaks, Calif.)
2021

Defects in GnRH Neuron Migration/Development and Hypothalamic-Pituitary Signaling Impact Clinical Variability of Kallmann Syndrome.

Genes
2021

Reduced Quality of Life and Sexual Satisfaction in Isolated Hypogonadotropic Hypogonadism.

Journal of clinical medicine
2021

SOX10 Mutation Screening for 117 Patients with Kallmann Syndrome.

Journal of the Endocrine Society
2021

A Family With Novel X-Linked Recessive Homozygous Mutation in ANOS1 (c.628_629 del, p.1210fs∗) in Kallmann Syndrome Associated Unilateral Ptosis: Case Report and Literature Review.

AACE clinical case reports
2021

Genetics of hypogonadotropic Hypogonadism-Human and mouse genes, inheritance, oligogenicity, and genetic counseling.

Molecular and cellular endocrinology
2021

Recent advances in understanding and managing Kallmann syndrome.

Faculty reviews
Ver todos os 442 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Kallmann.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Síndrome Kallmann e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A condição é causada por alterações genéticas que afetam a migração de neurônios produtores de GnRH e a formação dos bulbos olfatórios cerebrais. Vários genes podem estar envolvidos, incluindo CHD7, KISS1R, SOX10 e FGF8, transmitidos por diferentes padrões hereditários.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

8 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. [Kallmann syndrome in a girl caused by a novel CHD7 variant].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026PMID 41766158
  2. ORPHA:478
    Orphanet
  3. GARD:10771
    GARD (NIH)
  4. Q1165179
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Síndrome Kallmann. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/sindrome-kallmann

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Kallmann
Compêndio · Raras BR

Síndrome Kallmann

ORPHA:478 · MONDO:0018800
Prevalência
1-9 / 100 000
Herança
Autosomal dominant, Autosomal recessive, Multigenic/multifactorial, X-linked recessive
CID-10
E23.0 · Hipopituitarismo
CID-11
Ensaios
3 ativos
Início
Adolescent, Childhood
Prevalência
3.75 (Europe)
MedGen
UMLS
C0162809
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥇 Meta-análise

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara